Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission

Matuschek, Christiane; Bölke, Edwin; Roth, Stephan; Orth, Klaus; Lang, I.; Bojar, Hans; Janni, Johann Wolfgang; Audretsch, Werner; Nestle-Kraemling, Carolin; Lammering, Guido; Speer, Vanessa; Gripp, Stephan; Gerber, Peter Arne; Buhren, BA; Sauer, Rolf; Peiper, Matthias; Schauer, Matthias; Dommach, M.; Struse-Soll, K.; Budach, Wilfried

doi:10.1007/s00066-012-0162-8

Cited by 34 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of older case series and single arm trials report on preoperative RT with or without concomitant chemotherapy [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] (Table 1). In those that report on receptor status, hormone receptor positive tumours were less likely to achieve pathological complete response to chemoradiation (chemoRT) than other subtypes [16,17], which is unsurprising given the better complete pathological response rates following chemotherapy for higher risk subgroups.…”

Section: -Downstaging Of the Tumour To Enable Conservative Surgerymentioning

confidence: 99%

Preoperative breast radiation therapy: Indications and perspectives

Lightowlers

Boersma

Fourquet

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

Preoperative breast radiation therapy (RT) is not a new concept, but older studies failed to change practice. More recently, there has been interest in revisiting preoperative RT using modern techniques. This current perspective discusses the indications, summarises the published literature and then highlights current clinical trials, with particular attention to combining with novel drugs and optimising associated translational research.

show abstract

Section: -Downstaging Of the Tumour To Enable Conservative Surgerymentioning

confidence: 99%

Preoperative breast radiation therapy: Indications and perspectives

Lightowlers

Boersma

Fourquet

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…With the progress of examination techniques, early-stage cancer can now be detected and treated with the development of multidisciplinary therapies. Surgery and radiotherapy are used for local control, whereas chemotherapy is used for systemic control (2–8). The most recent examination techniques occasionally enable the detection of early-stage cancer, oligometastases and oligo-recurrence (9–11).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer

Aoyama

Ogawa²,

Yasuoka

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Linac-based stereotactic radiotherapy has little effect on the majority of advanced neoplasms. Therefore, the novel radiosensitizer Kochi oxydol-radiation therapy for unresectable carcinomas (KORTUC) II, which contains hydrogen peroxide and sodium hyaluronate, was developed. The effectiveness of KORTUC II for the treatment of chemotherapy-resistant supraclavicular lymph node metastases, recurrent breast cancer and stage IV primary breast cancer has previously been demonstrated. The present study evaluated the safety and efficacy of KORTUC II for patients with stage I primary breast cancer. A total of 15 patients (age range, 40–76 years) were enrolled. The injection of 3 ml of KORTUC II agent was initiated from the sixth radiotherapy fraction and was performed twice a week, under ultrasonographic guidance. The therapeutic effects were evaluated by PET-CT and/or MRI examinations prior to and following KORTUC II treatment. All patients exhibited complete responses and the overall survival rate was 100% after a follow-up period of five years. The mean duration of follow-up at the end of March 2015 was 53 months. Based on these results, KORTUC II treatment exhibited marked therapeutic effects with satisfactory treatment outcomes and an acceptable extent of adverse events.

show abstract

“…Previous studies of LABC have reported good pathological response rates with preoperative chemoradiotherapy, but all used “conventional” radiation techniques, often via tangential fields. Matuschek et al [11] reported a series of 315 LABC patients (cT1-cT4/cN0-N1). Preoperative EBRT delivered 50 Gy (5 × 2 Gy/week) to the whole breast, SCV/ICF nodes (255 of 315 patients), and IMC with a boost in 214 cases.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have used preoperative radiotherapy (combined with chemotherapy) in an attempt to downsize the tumor [6–11] making it amenable to surgery. However, these studies have only used conventional radiation techniques with considerable limitations in target volume coverage and sparing normal tissues.…”

Section: Introductionmentioning

confidence: 99%

Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool

Chira

Kirova²,

Liem³

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Background. We investigated the feasibility of helical tomotherapy (HT) for inoperable large breast tumors, after failing to achieve adequate treatment planning with conformal radiation techniques. Material and Methods. Five consecutive patients with locally advanced breast cancer (LABC) were treated by preoperative HT. All patients received up-front chemotherapy before HT. Irradiated volumes included breast and nodal areas (45–50 Gy) in 4 patients. One patient received a simultaneous integrated boost (55 Gy) to gross tumor volume (GTV) without lymph node irradiation. Acute toxicity was assessed with Common Toxicity Criteria for Adverse Events v.4. Patients were evaluated for surgery at the end of treatment. Results. Patients were staged IIB to IIIC (according to the AJCC staging system 2010). HT was associated in 4 patients with concomitant chemotherapy (5-fluorouracil and vinorelbine). Two patients were scored with grade 3 skin toxicity (had not completed HT) and one with grade 3 febrile neutropenia. One patient stopped HT with grade 2 skin toxicity. All patients were able to undergo mastectomy at a median interval of 43 days (31–52) from HT. Pathological partial response was seen in all patients. Conclusions. HT is feasible with acceptable toxicity profiles, potentially increased by chemotherapy. These preliminary results prompt us to consider a phase II study.

show abstract

Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission

Abstract: pCR identifies patients with a significantly better prognosis for long-term survival. However, a long time interval to surgery (> 2 months) increases the probability of pCR after NRT-CHX.

Cited by 34 publications

References 19 publications

Preoperative breast radiation therapy: Indications and perspectives

Preoperative breast radiation therapy: Indications and perspectives

Therapeutic results of a novel enzyme-targeting radiosensitization treatment, Kochi oxydol-radiation therapy for unresectable carcinomas II, in patients with stage I primary breast cancer

Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool

Contact Info

Product

Resources

About